Journal
JAMA ONCOLOGY
Volume 2, Issue 3, Pages 348-357Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jamaoncol.2015.4350
Keywords
-
Categories
Funding
- Cancer Research UK
- Medical Research Council
- Novartis
- Sanofi
- Pfizer
- Janssen
- Astellas
- Royal Marsden
- Institute of Cancer Research National Institute for Health Research, Biomedical Research Centre
- Cancer Research UK [3804, 13239, 12459, 10588, 19727] Funding Source: researchfish
- Medical Research Council [MC_UU_12023/6, MC_UU_12023/25, MR/K006584/1] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0611-10106, CL-2008-22-001] Funding Source: researchfish
- Prostate Cancer UK [PG12-49] Funding Source: researchfish
- Public Health Agency [SPI/3315/06] Funding Source: researchfish
- MRC [MC_UU_12023/6] Funding Source: UKRI
Ask authors/readers for more resources
IMPORTANCE The natural history of patients with newly diagnosed high-risk nonmetastatic (MO) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinical trial has assessed the role of RT in patients with node-positive (N+) MO disease. The STAMPEDE Trial includes such individuals, allowing an exploratory multivariate analysis of the impact of radical RT. OBJECTIVE To describe survival and the impact on failure-free survival of RT by nodal involvement in these patients. DESIGN, SETTING, AND PARTICIPANTS Cohort study using data collected for patients allocated to the control arm (standard-of-care only) of the STAMPEDE Trial between October 5, 2005, and May 1, 2014. Outcomes are presented as hazard ratios (HRs) with 95% CIs derived from adjusted Cox models; survival estimates are reported at 2 and 5 years. Participants were high-risk, hormone-naive patients with newly diagnosed MO prostate cancer starting long-term HT for the first time. Radiotherapy is encouraged in this group, but mandated for patients with node-negative (NO) MO disease only since November 2011. EXPOSURES Long-term HT either alone or with RT, as per local standard. Planned RT use was recorded at entry. MAIN OUTCOMES AND MEASURES Failure-free survival (FFS) and overall survival. RESULTS A total of 721 men with newly diagnosed MO disease were included: median age at entry, 66 (interquartile range [IQR], 61-72) years, median (IQR) prostate-specific antigen level of 43 (18-88) ng/mL. There were 40 deaths (31 owing to prostate cancer) with 17 months' median follow-up. Two-year survival was 96%(95% CI, 93%-97%) and 2-year FFS, 77% (95% CI, 73%-81%). Median (IQR) FFS was 63 (26 to not reached) months. Time to FFS was worse in patients with N+ disease (HR, 2.02 [95% CI, 1.46-2.81]) than in those with NO disease. Failure-free survival outcomes favored planned use of RT for patients with both NOMO (HR, 0.33 [95% CI, 0.18-0.61]) and N+MO disease (HR, 0.48 [95% CI, 0.29-0.79]). CONCLUSIONS AND RELEVANCE Survival for men entering the cohort with high-risk MO disease was higher than anticipated at study inception. These nonrandomized data were consistent with previous trials that support routine use of RT with HT in patients with NOMO disease. Additionally, the data suggest that the benefits of RT extend to men with N+MO disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available